Background: The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially biased. Prospective studies have had limited power, particularly for BRCA2 mutation carriers. Further, previous studies have not considered the effect of RRSO in the context of natural menopause.
Methods: A multi-centre prospective cohort of 2272 BRCA1 and 1605 BRCA2 mutation carriers was followed for a mean of 5.4 and 4.9 years, respectively; 426 women developed incident breast cancer. RRSO was modelled as a time-dependent covariate in Cox regression, and its effect assessed in premenopausal and postmenopausal women.
Results: There was no association between RRSO and breast cancer for BRCA1 (HR = 1.23; 95% CI 0.94-1.61) or BRCA2 (HR = 0.88; 95% CI 0.62-1.24) mutation carriers. For BRCA2 mutation carriers, HRs were 0.68 (95% CI 0.40-1.15) and 1.07 (95% CI 0.69-1.64) for RRSO carried out before or after age 45 years, respectively. The HR for BRCA2 mutation carriers decreased with increasing time since RRSO (HR = 0.51; 95% CI 0.26-0.99 for 5 years or longer after RRSO). Estimates for premenopausal women were similar.
Conclusion: We found no evidence that RRSO reduces breast cancer risk for BRCA1 mutation carriers. A potentially beneficial effect for BRCA2 mutation carriers was observed, particularly after 5 years following RRSO. These results may inform counselling and management of carriers with respect to RRSO.
Keywords: BRCA1; BRCA2; Breast cancer; Mutation; Risk-reducing salpingo-oophorectomy.
Conflict of interest statement
Wendy Chung reports potential conflict of interest from Regeneron and Biogen; Olivier Caron from AstraZeneca and IPSEN; Pascal Pujol, AstraZeneca, Genomic Health and Roche; D Gareth Evans, AstraZeneca and AmGen; Ros Eeles, Janssen-Cilag; Diane Eccles, Pierre Fabre, AstraZeneca; Karin Kast, Roche Pharma AG; and David Goldgar, University of Utah Foundation and Ambry Genetics. Anne-Marie Gerdes participated in an Advisory Board Meeting London in 2016, sponsored by Astra Zeneca about BRCA-testing in ovarian cancer.
Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.Cochrane Database Syst Rev. 2018 Aug 24;8(8):CD012464. doi: 10.1002/14651858.CD012464.pub2. Cochrane Database Syst Rev. 2018. PMID: 30141832 Free PMC article. Review.
Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.Eur J Cancer. 2020 Jun;132:53-60. doi: 10.1016/j.ejca.2020.03.009. Epub 2020 Apr 20. Eur J Cancer. 2020. PMID: 32325420
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.J Natl Cancer Inst. 2009 Jan 21;101(2):80-7. doi: 10.1093/jnci/djn442. Epub 2009 Jan 13. J Natl Cancer Inst. 2009. PMID: 19141781 Free PMC article.
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.J Clin Oncol. 2008 Mar 10;26(8):1331-7. doi: 10.1200/JCO.2007.13.9626. Epub 2008 Feb 11. J Clin Oncol. 2008. PMID: 18268356 Free PMC article. Clinical Trial.
Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.Crit Rev Oncol Hematol. 2018 Dec;132:111-115. doi: 10.1016/j.critrevonc.2018.09.018. Epub 2018 Oct 3. Crit Rev Oncol Hematol. 2018. PMID: 30447915 Review.
Cited by 1 article
Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.Breast Cancer Res. 2020 Feb 26;22(1):25. doi: 10.1186/s13058-020-01259-w. Breast Cancer Res. 2020. PMID: 32102695 Free PMC article.
- Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26(8):1331–1337. doi: 10.1200/JCO.2007.13.9626. - DOI - PMC - PubMed
- C12292/A11174/CRUK_/Cancer Research UK/United Kingdom
- R01 CA159868/CA/NCI NIH HHS/United States
- C1287/23382/CRUK_/Cancer Research UK/United Kingdom
- C1287/A17523/CRUK_/Cancer Research UK/United Kingdom